Obsidian Therapeutics is a biotechnology company based in Cambridge, Mass., using novel synthetic biology approaches to regulate protein levels in cell and gene therapies.
Obsidian’s technology is comprised of a drug-responsive domain paired with a therapeutic protein of interest. The expression of the protein can be regulated by FDA-approved small molecules.
In the absence of the small molecule, the drug-responsive domain is unstable, and the protein degrades. In the presence of the small molecule, the domain is folded, enabling protein expression. Obsidian can thus control the timing of protein expression, and the level of protein expressed, using FDA-approved drugs.
Obsidian can apply its technology to any modality, including controlling the proteins delivered by cell and gene therapies to treat serious diseases like cancer.